IQVIA Market Access Launch Pad is a dynamic and comprehensive suite of tools designed to support pharmaceutical companies in their product launch readiness.
When health solutions become suddenly and overwhelmingly popular, there is increased demand on communication channels that impact customer experience and solution access.
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.